The drugs comes with a warning label and the cost could be an issue for patients are it costs about $3,000 a month.
With more than 5 million customers, 23andMe has a trove of information about the links between genes and disease.
Clinical testing of drugs on dogs is a cruel practice, doesn't add value or provide data that is applicable to humans
The primary objection to the specific use of dogs in testing is thus simple — the data derived from dogs is not predictive enough to be applied to the case of humans
The fear is that if Narendra Modi capitulates to US pressure on India’s Intellectual Property Rights (IPR) regime, which it has been overtly and covertly exerting for years, it will make many lifesaving drugs unaffordable
On World Cancer Day, here is arithmetic to show that big pharma's justification for high prices of life-saving drugs is not the complete truth.
There has been a systematic effort by the western media, international business bodies and their trade proxies to malign India. Perhaps the biggest pressure came from the US, both by the government and trade and business organisations. <br /><br />
India's patent appeals board has revoked a patent granted to GlaxoSmithKline Plc's breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.
In the unresisted and rapidly rising cacophony against the FDA-tainted Ranbaxy, what get drowned unfortunately are voices that are vital to the country's drug industry and people's health.
It's abundantly clear that the Ranbaxy fiasco in the US, in which the company has to pay $500 million for allegedly selling adulterated drugs, is the big opportunity that the multinational drug companies have been waiting for to malign India.
Holding placards that said: "EU FTA kills patients", "FTA kills domestic production of medicine" about 250 people gathered at Jantar Mantar this afternoon urging the government to not sign the Free Trade Agreement with the European Union
The interim application of the multinational pharma major that Glenmark be restrained from manufacturing and selling the anti-diabetes medicines on the grounds that the salt used in the drugs were not of generic nature was denied by the court.<br /><br />
The United States is considering its response to the Supreme Court ruling against Novartis, which US drug manufacturers warn is the latest sign of a "deteriorating" environment for intellectual property rights in India.
Much of the new business will still come from cheap generics made by local companies, but Western firms are also seeking to put their brands on unpatented medicines, prompting the likes of Abbott Laboratories and Daiichi Sankyo to buy up Indian companies.
Our academic and research institutions have to make research a priority and the government has to liberally fund them. The bottomline of the Glivec and recent experiences is simple - we should get our priorities right. The rest will fall in place. <br /><br />
India is a country where pharma companies can do research and development at lower cost. Ignoring this fact will be detrimental for the Big Pharma.
<br /><br /> The decision is a setback for struggling AstraZeneca, which is battling to turn itself around as key drugs lose patent protection.